.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,192,576

« Back to Dashboard

Claims for Patent: 9,192,576

Title:Bromocriptine formulations
Abstract: The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycerine control in the treatment of type 2 diabetes.
Inventor(s): Cincotta; Anthony H. (Tiverton, RI), Bowe; Craig Michael (Encinitas, CA), Stearns; Paul Clark (San Diego, CA), Weston; Laura Jean (Escondido, CA)
Assignee: VeroScience LLC (Tiverton, RI)
Application Number:14/088,269
Patent Claims: 1. A dosage form comprising bromocriptine mesylate and one or more excipients in the form of an oral tablet; wherein the bromocriptine mesylate is present in an amount that provides a dose of at least about 0.8 mg of bromocriptine per said oral tablet; and wherein the oral tablet provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; wherein the bromocriptine mesylate has a particle size distribution with a span of about 2 or lower; and wherein the oral tablet has a dissolution profile wherein at least about 80% of the bromocriptine mesylate has been released at about 30 minutes, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

2. The dosage form of claim 1, wherein the bromocriptine mesylate has a Dv90 of less than about 10 .mu.m.

3. The dosage form of claim 1 wherein the oral tablet has a dissolution profile wherein at least about 90% of the bromocriptine mesylate has been released at about 30 minutes, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

4. The dosage form of claim 1, wherein the bromocriptine mesylate has a Dv90 of less than about 20 .mu.m.

5. The dosage form of claim 2 wherein the bromocriptine mesylate has a volume-based particle size distribution wherein not more than about 20% of the bromocriptine mesylate has a particle size of less than about 1 .mu.m.

6. The dosage form of claim 1 wherein the oral tablet has a dissolution profile wherein at least about 90% of the bromocriptine mesylate has been released at about 20 minutes when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

7. The dosage form of claim 1 wherein the oral tablet has a dissolution profile wherein at least about 50% of the bromocriptine mesylate has been released at about 7 minutes and not more than about 75% of the bromocriptine mesylate has been released at about 10 minutes when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

8. A dosage form comprising bromocriptine mesylate and one or more excipients in the form of an oral tablet; wherein the bromocriptine mesylate is present in an amount that provides a dose of at least about 0.8 mg of bromocriptine per said oral tablet; and wherein the oral tablet provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; wherein the bromocriptine mesylate has a particle size distribution with a span of about 2 or lower; and wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T.sub.max) of bromocriptine is between about 30 and about 60 minutes following administration of the oral tablet to the subject under fasting conditions or the T.sub.max of bromocriptine is between about 90 and about 120 minutes following administration of the oral tablet to the subject under high fat fed conditions.

9. The dosage form of claim 1 wherein the bromocriptine mesylate is present in an amount that provides a dose of about 0.8 mg of bromocriptine per said oral tablet.

10. A method of improving glycemic control in a type 2 diabetes patient, comprising administering to the patient an oral dosage form according to claim 1.

11. The dosage form of claim 1, wherein the bromocriptine mesylate is micronized.

12. The dosage form of claim 8, wherein the bromocriptine mesylate is micronized.

13. The method of claim 10, wherein the tablet is administered in the morning within about two hours after waking.

14. A method of improving glycemic control in a type 2 diabetes patient, comprising administering to the patient an oral dosage form according to claim 8.

15. The method of claim 14, wherein the tablet is administered in the morning within about two hours after waking.

16. A tablet comprising bromocriptine in micronized form and one or more excipients; wherein the tablet provides a dose of at least about 0.8 mg of bromocriptine per said oral tablet; and wherein the tablet provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; and wherein the tablet has a dissolution profile wherein at least about 80% of the bromocriptine has been released at about 30 minutes, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

17. The tablet of claim 16, wherein the bromocriptine is in the form of a salt of bromocriptine.

18. The tablet of claim 17, wherein the bromocriptine is in the form of bromocriptine mesylate.

19. The tablet of claim 16, wherein the bromocriptine has a Dv90 of less than about 20 .mu.m.

20. The tablet of claim 16, wherein the bromocriptine has a Dv90 of less than about 10 .mu.m.

21. The tablet of claim 16, wherein the bromocriptine has a volume-based particle size distribution wherein not more than about 20% of the bromocriptine has a particle size of less than about 1 .mu.m.

22. The tablet of claim 16, wherein the bromocriptine has a volume-based particle size distribution with a span of about 2 or lower.

23. The tablet of claim 16, wherein the tablet has a dissolution profile wherein at least about 90% of the bromocriptine has been released at about 30 minutes, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

24. The tablet of claim 16, wherein the tablet has a dissolution profile wherein not more than about 50% of the bromocriptine mesylate has been released at about 7 minutes and not more than about 75% of the bromocriptine mesylate has been released at about 10 minutes when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

25. The tablet of claim 16, wherein the tablet exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T.sub.max) of bromocriptine is between about 30 and about 60 minutes following administration of the tablet to the subject under fasting conditions or the T.sub.max of bromocriptine is between about 90 and about 120 minutes following administration of the tablet to the subject under high fat fed conditions.

26. A tablet comprising micronized bromocriptine mesylate and one or more excipients; wherein the micronized bromocriptine mesylate is present in an amount that provides a dose of at least about 0.8 mg of bromocriptine per tablet; wherein the micronized bromocriptine mesylate has a Dv90 of less than about 10 .mu.m, and wherein not more than about 20% of the bromocriptine mesylate has a particle size of less than about 1 .mu.m; and wherein the tablet provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein not more than about 50% of the bromocriptine mesylate has been released at about 7 minutes, not more than about 75% of the bromocriptine mesylate has been released at about 10 minutes, and at least about 80% of the bromocriptine mesylate has been released at about 30 minutes.

27. A method of improving glycemic control in a type 2 diabetes patient, comprising administering to the patient an oral dosage form according to claim 26.

28. The method of claim 27, wherein the tablet is administered in the morning within about two hours after waking.

29. The method of claim 28, wherein the tablet provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 90% of the bromocriptine mesylate has been released at about 30 minutes.

30. A tablet comprising micronized bromocriptine mesylate and one or more excipients; wherein the micronized bromocriptine mesylate is present in an amount that provides a dose of at least about 0.8 mg of bromocriptine per tablet; wherein the micronized bromocriptine mesylate has a Dv90 of less than about 10 .mu.m, and a volume-based particle size distribution with a span of about 2 or lower; and wherein the tablet provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 80% of the bromocriptine mesylate has been released at about 30 minutes.

31. A method of improving glycemic control in a type 2 diabetes patient, comprising administering to the patient an oral dosage form according to claim 30.

32. The method of claim 31, wherein the tablet is administered in the morning within about two hours after waking.

33. The method of claim 32, wherein the tablet provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 90% of the bromocriptine mesylate has been released at about 30 minutes.

34. A method for the manufacture of a bromocriptine mesylate tablet comprising: processing bromocriptine mesylate to reduce the average particle size of the bromocriptine mesylate to provide bromocriptine mesylate that has a Dv90 of less than about 10 .mu.m and wherein not more than about 20% of the bromocriptine mesylate has a particle size of less than about 1 .mu.m after the processing; blending the processed bromocriptine mesylate with excipients to form a mixture wherein the bromocriptine mesylate is substantially evenly distributed in the mixture, and compressing the mixture to form a tablet; wherein the tablet comprises bromocriptine mesylate in an amount that provides a dose of at least about 0.8 mg of bromocriptine; and wherein the tablet provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 80% of the bromocriptine mesylate has been released at about 30 minutes.

35. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising preparing at least one bromocriptine mesylate tablet by a method according to claim 34, and providing the bromocriptine mesylate tablet for oral administration to the patient.

36. The method of claim 35, wherein the tablet is administered in the morning within about two hours after waking.

37. The method of claim 36, wherein the tablet provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 90% of the bromocriptine mesylate has been released at about 30 minutes.

38. A method for the manufacture of a bromocriptine mesylate tablet comprising: determining that bromocriptine mesylate has a particle size distribution equivalent to a volume-based particle size distribution with a Dv90 of less than about 10 .mu.m and wherein not more than about 20% of the bromocriptine mesylate has a particle size of less than about 1 .mu.m; blending the bromocriptine mesylate of determined particle size distribution with excipients to form a mixture wherein the bromocriptine mesylate is substantially evenly distributed in the mixture, and compressing the mixture to form a tablet; wherein the tablet comprises bromocriptine mesylate in an amount that provides a dose of at least about 0.8 mg of bromocriptine; and wherein the tablet provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 80% of the bromocriptine mesylate has been released at about 30 minutes.

39. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising preparing at least one bromocriptine mesylate tablet by a method according to claim 38, and providing the bromocriptine mesylate tablet for oral administration to the patient.

40. The method of claim 39, wherein the tablet is administered in the morning within about two hours after waking.

41. The method of claim 40, wherein the tablet provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 90% of the bromocriptine mesylate has been released at about 30 minutes.

42. A method of improving glycemic control in a type 2 diabetes patient, comprising administering to the patient in the morning within about two hours after waking an oral dosage form comprising: micronized bromocriptine mesylate and one or more excipients in the form of an oral tablet; wherein the micronized bromocriptine mesylate is present in an amount that provides a dose of at least about 0.8 mg of bromocriptine per said oral tablet; and wherein the oral tablet provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; and wherein the oral tablet has a dissolution profile wherein at least about 90% of the bromocriptine mesylate has been released at about 30 minutes, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

43. A method of improving glycemic control in a type 2 diabetes patient, comprising administering to the patient in the morning within about two hours after waking an oral dosage form comprising: micronized bromocriptine mesylate and one or more excipients in the form of an oral tablet; wherein the micronized bromocriptine mesylate is present in an amount that provides a dose of at least about 0.8 mg of bromocriptine per said oral tablet; and wherein the oral tablet provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; and wherein not more than about 50% of the bromocriptine mesylate has been released at about 7 minutes and not more than about 75% of the bromocriptine mesylate has been released at about 10 minutes when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

44. A method of improving glycemic control in a type 2 diabetes patient, comprising administering to the patient in the morning within about two hours after waking an oral dosage form comprising: micronized bromocriptine mesylate and one or more excipients in the form of an oral tablet; wherein the micronized bromocriptine mesylate is present in an amount that provides a dose of at least about 0.8 mg of bromocriptine per said oral tablet; and wherein the oral tablet provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; and wherein said dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T.sub.max) of bromocriptine is between about 30 and about 60 minutes following administration of the dosage form to the subject under fasting conditions or the T.sub.max of bromocriptine is between about 90 and about 120 minutes following administration of the dosage form to the subject under high fat fed conditions.

45. A method of improving glycemic control in a type 2 diabetes patient, comprising administering to the patient in the morning within about two hours after waking an oral dosage form comprising: micronized bromocriptine mesylate and one or more excipients in the form of an oral tablet; wherein the micronized bromocriptine mesylate is present in an amount that provides a dose of at least about 0.8 mg of bromocriptine per said oral tablet; and wherein the oral tablet provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; and wherein the oral tablet has a dissolution profile wherein at least about 80% of the bromocriptine mesylate has been released at about 30 minutes, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

46. An dosage form comprising bromocriptine mesylate and one or more excipients in the form of an oral tablet; wherein the bromocriptine mesylate is present in an amount that provides a dose of at least about 0.8 mg of bromocriptine per said oral tablet; wherein the oral tablet provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; wherein the bromocriptine mesylate has a particle size distribution with a Dv90 of about 15 .mu.m or lower; and wherein the oral tablet has a dissolution profile wherein at least about 80% of the bromocriptine mesylate has been released at about 30 minutes, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

47. The dosage form of claim 46, wherein the bromocriptine mesylate has a Dv90 of less than about 10 .mu.m.

48. The dosage form of claim 46, wherein the bromocriptine mesylate has a volume-based particle size distribution with a span of about 2 or lower.

49. The dosage form of claim 46, wherein the oral tablet has a dissolution profile wherein at least about 90% of the bromocriptine mesylate has been released at about 30 minutes, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

50. The dosage form of claim 46, wherein the bromocriptine mesylate has a Dv99 of less than about 15 .mu.m.

51. The dosage form of claim 50, wherein the bromocriptine mesylate has a volume-based particle size distribution with a span of about 2 or lower.

52. The dosage form of claim 46, wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T.sub.max) of bromocriptine is between about 30 and about 60 minutes following administration of the oral tablet to the subject under fasting conditions or the T.sub.max of bromocriptine is between about 90 and about 120 minutes following administration of the oral tablet to the subject under high fat fed conditions.

53. A method of improving glycemic control in a type 2 diabetes patient, comprising administering to the patient an oral dosage form according to claim 46.

54. The method of claim 53, wherein the tablet is administered in the morning within about two hours after waking.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc